Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

We aimed to investigate whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state.

What inspired their development in the first place? It turns out your body produces natural versions of these drugs—also known as incretin hormones—in your gut. It may not be surprising that nutrients ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to ...

Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous ...

Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 programPivotal Phase 3 trials designed to leverage the ...

For Q3 2024, Aristotle Atlantic’s Large Cap Growth Composite posted a total return of 1.26% gross of fees, underperforming ...

Zealand Pharma AS (ZLDPF) showcases promising trial results and strategic partnerships while navigating high R&D expenses and ...

A previous study with this incretin triagonist delivered transenterically demonstrated pharmacodynamic effects comparable to subcutaneous injection. Rani also previously completed a study ...